Enjoy complimentary customisation on priority with our Enterprise License!
The regenerative medicine market size is forecast to increase by USD 70.11 billion at a CAGR of 23.31% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of chronic diseases, particularly in the geriatric population, and the resulting demand for innovative treatments. Genomic research and advancements in genome editing are driving the development of new therapies for neurodegenerative diseases, such as Alzheimer's, and conditions affecting the eye, including damage to the Choriocapillaris and Bruch's membrane, which can lead to vision loss. Additionally, regenerative medicine holds promise for the treatment of injuries to cartilage, tendons, ligaments, and muscle. However, the market faces challenges, including the uncertain regulatory approval process for regenerative medicine products, which can hinder market growth and limit the availability of these potentially life-changing therapies and medical technologies to patients. Clinical trials are underway to address these challenges and bring new regenerative medicine solutions to market.
To learn more about the regenerative medicine market report, Request Free Sample
Regenerative medicine is a rapidly evolving field that focuses on the repair or replacement of damaged or diseased cells, tissues, and organs. This market is witnessing significant growth due to the increasing prevalence of blood cancers and rare diseases, which require personalized medicine approaches. Gene therapy and CRISPR therapy are two innovative techniques gaining traction in this market, offering potential solutions for chronic genetic disorders. The healthcare expenditure on regenerative medicine is expected to increase due to the potential of these treatments to address unmet medical needs. Key areas of focus include research on the trim72 protein for vasculature repair, skeletal muscles for orthopedics, and platelet-rich plasma for wound care.
Moreover, the R&D capabilities are being strengthened through research grants and collaborations, with companies like Integra Lifesciences and others investing in cell therapy, Car-T treatment, and tissue engineering. The innovative pipeline candidates in this field hold immense promise for addressing various medical conditions, including oncology and rare diseases.
The regenerative medicine market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The oncology segment is estimated to witness significant growth during the forecast period. The regenerative medicines market is experiencing substantial growth, particularly in the oncology application segment. Factors driving this trend include the rising incidence of cancer worldwide. According to the World Health Organization (WHO) and the European Medicines Agency (EMA), the number of cancer cases is projected to increase, with an estimated 14.6 million cases and a crude incidence rate of 100.4 per 100,000 in India in 2022.
Notable companies in this field, such as Integra LifeSciences, are developing innovative pipeline candidates, including cellular therapies like CAR-T treatment, tissue engineering, and platelet rich plasma. These advancements are transforming the landscape of oncology, as well as orthopedics, wound care, and other medical applications. Hospitals and clinics are increasingly integrating these technologies into their offerings, expanding their capabilities and improving patient outcomes through minimally invasive surgeries and personalized treatments.
Get a glance at the market share of various segments. Request Free Sample
The oncology segment was valued at USD 5.58 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 48% to the growth of the global regenerative medicine market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The North American regenerative medicine market is witnessing significant growth, with approximately 510 companies engaged in its production and development. Key companies, including Integra LifeSciences, MiMedx, Organogenesis, and Zimmer Biomet Holdings Inc., are bolstering market expansion through new product launches and strategic sales force reorganization. Factors fueling this growth include the increasing prevalence of chronic and acute diseases, a rapidly aging population, and heightened awareness of regenerative therapies and procedures among end-users. Additionally, the adoption of cell and tissue-based therapies, gene therapies, and the presence of tissue banks are significant market drivers. In oncology, orthopedics, wound care, and hospitals and clinics, regenerative medicine is increasingly being utilized in surgeries and treatments, such as CAR-T and platelet rich plasma therapies.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of chronic diseases is the key driver of regenerative medicine market growth. The market is witnessing significant growth due to the increasing prevalence of chronic diseases such as blood cancers, rare diseases, and chronic genetic disorders. These conditions put a substantial strain on healthcare expenditure and patient quality of life. Personalized medicine approaches, including gene therapy and CRISPR technology, are gaining traction as potential solutions for treating these conditions. The TRIM72 protein, for instance, has shown promise in gene therapy for various diseases, including cancer and neurodegenerative disorders. Moreover, advances in regenerative medicine are also being explored for the treatment of conditions affecting the vasculature and skeletal muscles, such as vasculitis and muscular dystrophies.
Moreover, government organizations and research grants are providing substantial funding for R&D capabilities in this field. Strategic acquisitions and collaborations among key players are also driving innovation and market expansion. Overall, the market holds immense potential for improving patient outcomes and reducing the burden of chronic diseases on healthcare systems.
Increasing number of clinical trials is the upcoming trend in the market. The regenerative medicine market is experiencing a notable growth trajectory, driven by the escalating number of clinical trials for various applications. This trend is largely fueled by the growing initiatives and support from international and national public and private organizations. Regenerative medicine products are progressing through various stages of development, from the discovery and preclinical phase to mid- and late-stage clinical trials. As of July 2022, over 1,400 companies worldwide are actively engaged in regenerative medicine research. These companies are expanding their reach geographically and indicatively, leading to an increase in the overall number of clinical trials.
Several advancements in technologies such as gene therapy, CRISPR therapy, and personalized medicine for conditions like blood cancers, rare diseases, chronic genetic disorders, and vasculature and skeletal muscle disorders are contributing to this growth. Government organizations and research grants, as well as strategic acquisitions and collaborations, are further bolstering the R&D capabilities in this field.
Uncertain regulatory approval for regenerative medicine products is a key challenge affecting regenerative medicine market growth. Regenerative medicine, encompassing gene therapy, cell therapy, and tissue engineering and recreation, has witnessed significant advancements in recent years, particularly in the treatment of blood cancers and rare diseases. Personalized medicine approaches, such as CRISPR therapy for chronic genetic disorders, are driving innovation in this field. However, the complex nature of these therapies and the need for extensive research on the TRIM72 protein, vasculature, and skeletal muscles present challenges. Regulatory approvals and healthcare expenditure are crucial factors influencing market growth.
Government organizations and research grants are pivotal in funding R&D capabilities, while strategic acquisitions and collaborations expand market reach. Despite these efforts, the clinical impact of some regenerative medicine products may not be immediately apparent, with stringent regulations and uncertainty surrounding regulatory approval posing significant challenges for companies.
The regenerative medicine market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the regenerative medicine market growth analysis report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers regenerative medicine solutions such as Alloderm select and Alloderm.
The regenerative medicine market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Regenerative medicine is an emerging field in medical science that focuses on the repair or replacement of damaged tissues and organs using innovative approaches such as cell therapy, tissue engineering, and molecular medicines. This market encompasses various therapeutic areas including blood cancers, rare diseases, chronic genetic disorders, and oncology. The market is driven by the increasing prevalence of age-related disorders, diabetes type 1 & 2, and cancer-related deaths. Regenerative medicine includes various product segments such as cell therapy, tissue-based regenerative therapies, and molecular medicines. The cell therapy segment includes innovative pipeline candidates like CAR-T treatment and T-cell therapy platforms. Moreover, tissue engineering focuses on the development of new tissues using nanotechnology and 3D printing. The market is witnessing significant investments from government organizations, academic research institutes, and private companies.
Research grants, strategic acquisitions, and R&D capabilities are key drivers of growth in this market. The orthopedics segment, including regenerative knee treatments and musculoskeletal treatments, is a significant contributor to the market. Regenerative medicine is also being explored for neurodegenerative diseases like Alzheimer's, spinal cord injuries, and vision disorders such as choriocapillaris and Bruch's membrane damage. The market is expected to grow significantly due to the adaptive regulatory approaches, funding initiatives, and the potential of gene editing technology. The therapeutic category includes oncology, cardiovascular, and dermatology segments. Regenerative medicine offers a promising alternative to traditional surgeries and conventional treatment approaches for various conditions. The EMA and FDA have granted RMAT designation and orphan drug designations to several regenerative medicine products.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
178 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 23.31% |
|
Market growth 2024-2028 |
USD 70.11 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
22.43 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 48% |
|
Key countries |
US, Germany, UK, Japan, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Holdings Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., and Zimmer Biomet Holdings Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our regenerative medicine market forecast report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this regenerative medicine market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
